Savara (NASDAQ:SVRA) Trading 6% Higher

Savara Inc (NASDAQ:SVRA)’s share price rose 6% during trading on Monday . The stock traded as high as $4.45 and last traded at $4.45. Approximately 1,005,176 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 1,195,491 shares. The stock had previously closed at $4.20.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Oppenheimer lifted their price target on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Savara in a research report on Wednesday, August 14th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Monday, September 9th. Finally, Guggenheim lifted their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.17.

Savara Price Performance

The company’s 50 day simple moving average is $4.40 and its 200-day simple moving average is $4.51. The company has a market capitalization of $613.56 million, a price-to-earnings ratio of -12.00 and a beta of 0.97. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, equities research analysts predict that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently added to or reduced their stakes in SVRA. Jump Financial LLC lifted its holdings in shares of Savara by 320.3% during the 4th quarter. Jump Financial LLC now owns 136,700 shares of the company’s stock valued at $642,000 after acquiring an additional 104,174 shares in the last quarter. Superstring Capital Management LP bought a new position in Savara during the fourth quarter worth $3,827,000. Wellington Management Group LLP acquired a new position in shares of Savara in the 4th quarter valued at about $9,683,000. Sivia Capital Partners LLC bought a new position in shares of Savara during the fourth quarter valued at approximately $169,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Savara by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock worth $130,000 after buying an additional 10,381 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.